Skip to main content

Table 1 Study characteristics

From: Effectiveness of Resistance Training and Associated Program Characteristics in Patients at Risk for Type 2 Diabetes: a Systematic Review and Meta-analysis

Study Country Number of participants Age Metabolic risk criteria Duration (weeks) Medications Findings
Alvarez et al. [40] Chile CON=13 RT=8 CON= 40.1 ± 11.4
RT=33.9 ± 9.3
Elevated glucose 12 NR ↓HOMA-IR, FPG (p=0.011) with RT
Dai et al. [47] China CON=35 RT=31 CON=55–75
RT=55–75
Prediabetes 96 Lipid lowering (3 CON, 6 RT) ↓HbA1c, FPG (p<0.001), TC, LDL (p<0.001), TG (p=0.03), and ↑HDL (p<0.001) with RT
Devallance et al. [48] USA CON=16 RT=14 CON=51 ± 4
RT=51 ± 3
Metabolic syndrome 8 Antihypertensive (41% CON, 38% RT). Cholesterol lowering (19% CON, 23% RT) No significant changes in outcomes of interest
Flández et al. [49] Chile CON=20 RT=20 CON=46.47 ± 3.71
RT= 46.47 ± 3.71
Metabolic syndrome 12 NR ↓HbA1c (p<0.05) with RT
Huffman et al. [50] USA CON=20 RT=20 CON=18–70
RT=18–70
Dyslipidemia 24 NR No significant changes in outcomes of interest
Korkmaz et al. [45]; Venojärvi et al. [46] Finland CON=40 RT=36 CON=54 ± 1
RT=40–65
Impaired glucose regulation 12 Lipid lowering (25% CON, 22% RT). Antihypertensive (30% CON, 33% RT). No significant changes in outcomes of interest
Levinger et al. [51] Australia CON=15 RT=15 CON=52.3 ± 5.8
RT=51.6 ± 7.1
Metabolic risk factors according to the International Diabetes Federation 10 Antihypertensives, cholesterol lowering, and metformin. No significant changes in outcomes of interest
Levinger et al. [52] Australia CON=14 RT=15 CON=51.21 ± 7.33
RT=51 ± 7
Metabolic risk factors according to the International Diabetes Federation 10 Antihypertensives, cholesterol lowering, and metformin. No significant changes in outcomes of interest
Mager et al. [53] Finland CON=18 RT=14 CON=60 ± 7
RT=60 ± 7
Impaired fasting glucose and 2 metabolic syndrome factors 33 NR No significant changes in outcomes of interest
Marcus et al. [54] USA CON=6 RT=10 CON=53.2 ± 6.5
RT=56.3 ± 6.4
Impaired glucose tolerance 12 NR No significant changes in outcomes of interest
Stensvold et al. [55] Norway CON=11 RT=11 CON=47.3 ± 10.2
RT=50.9 ± 7.6
Metabolic syndrome 12 Antihypertensive and lipid lowering. (4 CON, 8 RT). ↓WC with RT
Turri-Silva et al. [56] Brazil CON=12 RT=19 CON=51.21 ± 7.33
RT=51.42 ± 5.22
Metabolic syndrome 12 NR No significant changes in outcomes of interest
Yuan et al. [44] China CON=83 RT=82 CON=60.73 ± 5.83
RT=59.91 ± 5.92
Prediabetes 24 Antihypertensives and cholesterol lowering. ↓HbA1c (p<0.001), BMI, SBP (p<0.05) with RT
Yan et al. [43] China CON=35 RT=35 CON=60.31 ± 7.56
RT=62.06 ± 8.11
Prediabetes 24 NR ↓FPG (p=0.004) with RT
  1. NR not reported, CON control, RT resistance training, HbA1c glycosylated hemoglobin, FPG fasting plasma glucose, TC total cholesterol, LDL low-density lipoprotein, HDL high-density lipoprotein, BMI body mass index, SBP systolic blood pressure